US stocks lose faith in the Trump bump
US stocks hit new records in March, but have drifted downwards since then as more and more investors have decided that Trump looks both capricious and ineffectual.
Ralph Waldo Emerson said that "a foolish consistency is the hobgoblin of little minds". Donald Trump "is proving to be anything but small-minded", says Randall Forsyth in Barron's. He has produced "several head-snapping reversals" of previous positions. China is apparently no longer a currency manipulator. Janet Yellen may, after all, get another term at the US Federal Reserve. After decrying US overseas adventures, he has waded into Syria and is threatening North Korea.
As far as markets are concerned, says Larry Elliott in The Guardian, the impression is that Trump is "dangerously unpredictable". It's pretty clear now that "he is making it up as he goes along". The failure to replace Obamacare "was the first sign of trouble", since it cast doubt on the White House's economic stimulus package. History shows that "even the most effective presidents barely get through Congress half of what they campaigned on", notes David Rosenberg of Gluskin Sheff.
That apparently comes as news to US investors, whose enthusiasm for equities since Trump's election suggests they have priced in a hefty stimulus through tax cuts, deregulation and higher spending on infrastructure. Stocks hit new records in March, but have drifted downwards since then as more and more investors have decided that Trump looks both capricious and ineffectual.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
It hardly helps that doubts over the strength of the US economy are growing. Last week we highlighted the split between the buoyant soft data business surveys and confidence indicators and the less impressive hard data, or official figures. Retail sales slipped for a second successive month in March, while the annual rate of inflation fell by 0.3%. There has also been a slowdown in bank lending. Total loans and leases extended by commercial banks were up by just 3.8% year-on-year in late March, compared to 6.4% for 2016 as a whole. Given this backdrop, there is a great deal at stake this earnings season: profits are expected to rise by 9.2% year-on-year, the fastest growth since 2011, while revenue growth is also supposed to return with a vengeance. Sales are expected to grow by 6.9%. With valuations historically overstretched, "there is no scope for disappointment", says Fidelity's Tom Stevenson in The Daily Telegraph.
So with the outlook for growth and earnings uncertain for now, and Trump's "Dr Strangelove-style foreign policy antics", it's no wonder stocks have faltered. "US defence stocks look like a decent bet," concludes Elliott. "The rest of the market does not."
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Andrew is the editor of MoneyWeek magazine. He grew up in Vienna and studied at the University of St Andrews, where he gained a first-class MA in geography & international relations.
After graduating he began to contribute to the foreign page of The Week and soon afterwards joined MoneyWeek at its inception in October 2000. He helped Merryn Somerset Webb establish it as Britain’s best-selling financial magazine, contributing to every section of the publication and specialising in macroeconomics and stockmarkets, before going part-time.
His freelance projects have included a 2009 relaunch of The Pharma Letter, where he covered corporate news and political developments in the German pharmaceuticals market for two years, and a multiyear stint as deputy editor of the Barclays account at Redwood, a marketing agency.
Andrew has been editing MoneyWeek since 2018, and continues to specialise in investment and news in German-speaking countries owing to his fluent command of the language.
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published